Inhibition of interleukin 2 production and alteration of interleukin 2 mRNA processing by human T-T cell hybridoma-derived suppressor factors.
We investigated the mechanisms by which two human T-T cell hybridoma-derived suppressor factors (SFs) (designated 160 and 169) (Platsoucas et al., Hybridoma 1987;6:589; Kunicka et al., Hybridoma 1989;8:127) inhibit the proliferative response to mitogens by human peripheral blood mononuclear cells (PBMCs). Interleukin 2 (IL-2) production by human PBMCs cultured with concanavalin A or OKT3 monoclonal antibody for 12 or 36 hr in the presence of 160 or 169 SF was found to be inhibited > 80% when compared to control PBMC cultures stimulated with mitogen in the absence of SFs. This suppression of IL-2 production was not due to the SFs interfering with IL-2-induced proliferation of the IL-2-dependent murine cell clone used to determine the levels of IL-2. The proliferative responses of SF-treated PBMCs could not be restored by addition of exogenous recombinant human IL-2 (rIL-2) (1-100 U/ml). Furthermore, inhibition of the proliferative responses by the SFs could not be reversed by addition of exogenous rIL-1, rIL-2, or rIL-4 alone or in paired combinations. The expression of IL-2 receptors (TAC Ag) on concanavalin A-activated cultures at 12- or 36-hr time points was not affected by treatment with the SFs. Both the 160 and 169 hybridoma-derived SFs were found to cause the accumulation of an mRNA of 2.8 kb that hybridized with an IL-2-specific oligonucleotide probe. This 2.8-kb transcript was in addition to the expected 1.0-kb, transiently expressed IL-2 message, and it could be superinduced in the presence of cycloheximide. These results suggest that these SFs may be influencing RNA splicing pathways. These SFs appear to be useful molecules for probing the regulatory controls of lymphocyte proliferation and may constitute important physiological regulators of the immune response. In addition, they may have clinical activity for the treatment of patients that received transplants, patients with autoimmune diseases, and others.
Fox
F E
FE
Department of Immunology, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
Chernajovsky
Y
Y
Platsoucas
C D
CD
D000328:Adult; D001483:Base Sequence; D015152:Blotting, Northern; D006801:Humans; D006825:Hybridomas; D007376:Interleukin-2 / Q000096:biosynthesis* / Q000235:genetics; D007553:Isotope Labeling; D008969:Molecular Sequence Data; D010761:Phosphorus Radioisotopes; D012323:RNA Processing, Post-Transcriptional; D012333:RNA, Messenger / Q000096:biosynthesis / Q000378:metabolism*; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D013491:Suppressor Factors, Immunologic / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D007376:Interleukin-2; D010761:Phosphorus Radioisotopes; D012333:RNA, Messenger; D015375:Receptors, Interleukin-2; D013491:Suppressor Factors, Immunologic